drugset / Trial / NCT02182297
Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this trial was to investigate safety, tolerability, and pharmacokinetics of BI 201335 ZW after administration of single rising doses from 40 mg to 480 mg of BI 201335 NA in healthy Japanese male volunteers.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faldaprevir | Small molecule | 40 mg | Oral |
| Subject | Faldaprevir | Small molecule | 480 mg | Oral |
Indications
No indication recorded.